Oncology

Latest News

Within 5 years, the risk of SCC in particular was heightened among patients with MMP. | Image credit: wavebreak3 - stock.adobe.com

Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers

By AJMC Contributor

April 21st 2025

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.

AI technology | Image: Adobe Stock

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

IVBM Atlanta | Image credit: AJMC

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

AJMC

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 22nd 2016

What We're Reading: Seeking a Moratorium on New Drug Ads

What we're reading, February 22, 2016: new legislation proposes placing a 3-year moratorium on advertising newly approved drugs; the prevalence and incidence of stroke among young adults has increased significantly; and more women with breast cancer are choosing outpatient mastectomies.

February 22nd 2016

Procedural Vote May Push Califf Through to Lead the FDA

Surabhi Dangi-Garimella, PhD

Support from at least 60 senators during today's procedural vote will ensure a final confirmation vote for Robert Califf, MD, likely Tuesday.

This Week in Managed Care: February 20, 2016

February 20th 2016

This Week in Managed Care: February 20, 2016

This week's top managed care stories included the release of 7 core sets of quality measures, more evidence that value-based insurance design works to lower costs, and the FDA assigns breakthrough designation to AstraZeneca's PD-L1 inhibitor.

February 19th 2016

Patients With Head and Neck Cancer Face Lifestyle Alterations and Poor Survival

Surabhi Dangi-Garimella, PhD

Two studies presented at the ongoing 2016 Multidisciplinary Head and Neck Cancer Symposium report on financial hurdles faced by patients diagnosed with head and neck cancer that result in lifestyle modifications, advanced disease, and worse outcomes.

February 18th 2016

Immuno-Oncology Agents Are Not Above Resistance, Study Shows

Surabhi Dangi-Garimella, PhD

A new study, published in Nature Communications, has delineated a mechanism that could help explain the resistance that is emerging with the new immuno-oncology agents such as PD-1 and PD-L1.

February 17th 2016

Task Force Recommends Post-Operative Colonoscopy Over Endoscopy for Improved Outcomes in CRC

Surabhi Dangi-Garimella, PhD

A Task Force composed of gastroenterology specialists, with a special interest in colorectal cancer, has released updated recommendations urging post-operative colonoscopy instead of endoscopy to improve survival.

February 17th 2016

Anti—PD-L1 Agent, Durvalumab, Gets Breakthrough for Bladder Cancer

Durvalumab is being developed for the treatment of PD-L1—positive patients with inoperable or metastatic urothelial bladder cancer

February 17th 2016

AJMC's Evidence-Based Oncology Takes a Fresh Look at Massive Impact of Immuno-Oncology

Evidence-Based Oncology, the multistakeholder publication of The American Journal of Managed Care devoted to cancer care, revisits the rapidly evolving field of immuno-oncology in its current issue. While one author calls the clinical impact of “tsunami proportions,” the healthcare system is grappling with how to pay for these therapies.

February 16th 2016

CMS' Core Oncology Measures - A Work in Progress

Surabhi Dangi-Garimella, PhD

CMS, in collaboration with a working group of national organizations, has developed a set of Medical Oncology Measures to improve quality of care and avoid redundancy for providers of care.

February 16th 2016

Humana Uncommitted on Cologuard Test, Faces Lawsuit

Surabhi Dangi-Garimella, PhD

A noninvasive colorectal cancer screening test manufactured by Exact Sciences, which received CMS coverage within months of its FDA approval, is not included under Humana’s coverage policy

February 15th 2016

Shortcomings of Written Informed Consent Forms

Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials.

February 15th 2016

Study Identifies Biomarkers and Potential Targets in Obesity-Associated Cancers

Surabhi Dangi-Garimella, PhD

Inhibiting the PIGF/VEGFR-1 signaling regressed tumor growth in obese, but not in lean mice, the author report.

February 12th 2016

Socioeconomic Status an Important Determinant of HPV Vaccination

Surabhi Dangi-Garimella, PhD

A study published in Cancer Epidemiology, Biomarkers & Prevention has identified geographic and ethnic factors as an important determinant of vaccinating against the human papillomavirus.

February 12th 2016

UK Regulators Perceive Value of Nivolumab in RCC

Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.

February 12th 2016

FDA Update in Oncology, February 2016

Surabhi Dangi-Garimella, PhD

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

February 12th 2016

Managed Care Updates in Oncology, February 2016

Surabhi Dangi-Garimella, PhD

A summary of updated breast cancer screening guidelines, MEDPAC recommendations for 340B, and disparity in survival of young patients with Hodgkin lymphoma.

February 11th 2016

Does Genetic Testing Impact Treatment Decisions in Breast Cancer?

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology found that the knowledge of genetic risk influenced surgical treatment decisions in women younger than 40 years who were diagnosed with breast cancer.

February 11th 2016

Cancer MoonShot 2020 Proposes a Collaborative Precision Cancer Care Model

Surabhi Dangi-Garimella, PhD

At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.

February 11th 2016

Shaping the Future of Immuno-Oncology

Joseph Alvarnas, MD

While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.

February 11th 2016

Study Compares Filgrastim vs Tbo-Filgrastim in Patients With Myeloma

While there are no significant differences in the results between filgrastim and tbo-filgrastim in a clinical setting, tbo-filgrastim offers significant cost savings over filgrastim.

February 10th 2016

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD

Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.

February 10th 2016

Patient Assistance: Implementing Preventative Steps to Ensure Financial Wellness

Jacqueline Cab&aacute n Charles Lynch

An overview of patient assistance programs at Smilow Cancer Hospital at Yale-New Haven, including their innovative hospital-based explanation of benefits form, which can eliminate patient responsibilities and help expedite the turnaround times for payment processing with copay assistance.

February 10th 2016

Patient Access to Immuno-Oncology Agents - A US Policy Perspective

Surabhi Dangi-Garimella, PhD

The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?

February 10th 2016

Study Hopes to Resolve Questions About Management of Pre-Cancers of the Breast

As physicians and researchers question whether certain treatments for early signs of breast cancer are necessary, the first large US study will seek to determine the best way to manage ductal carcinoma in situ.

February 9th 2016

Strong Gains for Healthcare and Research in President Obama's 2017 Budget

Surabhi Dangi-Garimella, PhD

Innovation has remained high on the administration’s agenda, as is evident from the allocations to tackle climate changes as well as find treatments for devastating health conditions.

February 9th 2016

Access to Immuno-Oncology Therapies - European Policy Perspective

Suzanne Wait, PhD

Ensuring rapid, appropriate, and sustainable access to immuno-oncology therapies for patients in Europe: what role can policies play?

February 8th 2016

ASCO Recommends Biomarker Use to Guide Early Breast Cancer Therapy Decisions

Surabhi Dangi-Garimella, PhD

The panel members that have proposed the recommendations have found clinical utility for several genomic tests to guide clinical decision in women with early stage breast cancer.

February 8th 2016

PhRMA Plans Targeted Ad Campaign in Wake of Focus on Drug Costs

The ads will be targeted at about 7000 "influencers" including lawmakers who could control whether drug prices are regulated. Many have called for Medicare to gain the right to negotiate drug prices.

February 8th 2016

Evolving Practices in Managing Costly Immunotherapy

Carina Verdier Dolan, PharmD, BCOP

To address the nationwide concern of costly immunotherapy agents, this article features health system inpatient and outpatient strategies that can help mitigate their costs.

February 8th 2016

PCPs Diligent With Following USPSTF Recommendations on PSA Testing

Surabhi Dangi-Garimella, PhD

Using data gathered from the National Ambulatory Medical Care Survey, the authors of a JAMA Internal Medicine study identified a significant decrease in PSA testing referrals by primary care physicians compared with urologists.

...

107 108 109 110 111 112 113 114 115

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions